COMPUGEN LTD
CGENNasdaq
$2.37
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↑ +50.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$222.3M
Enterprise Value
$122.5M
P/E
6.2
P/S
3.1
P/B
2.2
EV/EBITDA
3.9
PEG
—
FCF Yield
14.1%
Dividend Yield
—
Revenue (TTM)
$72.8M
Net Income (TTM)
$35.3M
Free Cash Flow (TTM)
$31.3M
Gross Margin
87.3%
Operating Margin
43.0%
Net Margin
48.6%
ROE
34.4%
ROIC
1097.5%
Debt / Equity
—
Net Cash
$99.9M
Return 1Y
+49.1%
Company profile
Compugen Ltd. researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, are in clinical study in patients with advanced or metastatic non-small cell lung cancer.
- CEO
- Anat Cohen-Dayag
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Website
- cgen.com
Management & directors
- Levine ZuritSVP, Business Development
- Ophir EranPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Gross profit | $1.9M | $5.3M | $6.5M | $31.5M | $19.9M | $63.5M |
| Operating income | -$31.5M | -$35.1M | -$35.4M | -$13.0M | -$14.9M | $31.3M |
| Net income | -$29.7M | -$34.2M | -$33.7M | -$18.8M | -$14.2M | $35.3M |
| Diluted EPS | -$0.37 | -$0.41 | -$0.39 | -$0.21 | -$0.16 | $0.38 |
| Operating cash flow | -$28.3M | -$22.7M | -$34.1M | -$35.9M | $49.6M | $31.6M |
| Free cash flow | -$28.5M | -$23.0M | -$34.6M | -$36.1M | $49.5M | $31.3M |
| Gross margin | 97.0% | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Operating margin | -1574.8% | -584.6% | -471.7% | -38.8% | -53.4% | 43.1% |
| Net margin | -1484.9% | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
No quarterly data.
Company news
Jul 20, 2026
Jun 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Levine Zurit· SVP, Business Development | Sale | 1,875 | $2.50 | $4,687.50 | filing |
| 2026-07-09 | Levine Zurit· SVP, Business Development | Option exercise | 1,875 | $0.83 | $1,554.75 | filing |
| 2026-04-24 | Ophir Eran· President and CEO | Sale | 5,000 | $3.20 | $16,000.50 | filing |
| 2026-04-24 | Levine Zurit· SVP, Business Development | Sale | 2,000 | $3.20 | $6,400.00 | filing |
| 2026-04-24 | Ophir Eran· President and CEO | Option exercise | 5,000 | $0.83 | $4,146.00 | filing |
| 2026-04-24 | Levine Zurit· SVP, Business Development | Option exercise | 2,000 | $1.15 | $2,300.00 | filing |
| 2026-04-14 | Ophir Eran· President and CEO | Sale | 5,000 | $2.90 | $14,521.00 | filing |
| 2026-04-14 | Levine Zurit· SVP, Business Development | Sale | 2,000 | $2.80 | $5,600.00 | filing |
| 2026-04-14 | Ophir Eran· President and CEO | Option exercise | 5,000 | $0.83 | $4,146.00 | filing |
| 2026-04-14 | Levine Zurit· SVP, Business Development | Option exercise | 2,000 | $1.15 | $2,300.00 | filing |
| 2026-04-10 | Levine Zurit· SVP, Business Development | Sale | 3,125 | $2.56 | $8,012.50 | filing |
| 2026-04-10 | Levine Zurit· SVP, Business Development | Sale | 3,125 | $2.56 | $8,012.50 | filing |
| 2026-04-10 | Levine Zurit· SVP, Business Development | Option exercise | 2,000 | $1.15 | $2,300.00 | filing |
| 2026-04-10 | Levine Zurit· SVP, Business Development | Option exercise | 2,000 | $1.15 | $2,300.00 | filing |
| 2026-04-10 | Levine Zurit· SVP, Business Development | Option exercise | 1,125 | $0.83 | $932.85 | filing |
| 2026-04-10 | Levine Zurit· SVP, Business Development | Option exercise | 1,125 | $0.83 | $932.85 | filing |
| 2026-04-08 | Levine Zurit· SVP, Business Development | Sale | 5,375 | $2.42 | $13,007.50 | filing |
| 2026-04-08 | Levine Zurit· SVP, Business Development | Option exercise | 4,375 | $0.83 | $3,627.75 | filing |
| 2026-04-08 | Levine Zurit· SVP, Business Development | Option exercise | 1,000 | $1.15 | $1,150.00 | filing |
| 2026-04-07 | Levine Zurit· SVP, Business Development | Sale | 2,500 | $2.30 | $5,750.00 | filing |
| 2026-04-07 | Levine Zurit· SVP, Business Development | Option exercise | 2,500 | $0.83 | $2,073.00 | filing |
| 2026-04-01 | Ophir Eran· President and CEO | Sale | 5,625 | $2.21 | $12,412.69 | filing |
| 2026-04-01 | Levine Zurit· SVP, Business Development | Sale | 3,500 | $2.20 | $7,700.00 | filing |
| 2026-04-01 | Ophir Eran· President and CEO | Option exercise | 5,625 | $0.83 | $4,664.25 | filing |
| 2026-04-01 | Levine Zurit· SVP, Business Development | Option exercise | 2,500 | $0.83 | $2,073.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.